AWARDDEFINITIVE CONTRACTSmall business
Definitive contract 75A50122C00061MAPP BIOPHARMACEUTICAL, INC.
Overview
Award facts
- Net obligations
- $220.92M
- $220,916,162of $942.78M potential value
- Period of performance
- Sep 30, 2022 to Sep 30, 2030
- Ends in about 4 years
- Modifications
- 24
- Latest action Nov 9, 2026
- Contract type
- Definitive contract
- PIID 75A50122C00061
Description of requirement
PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES
Dates and value
- Award date
- Signed on Sep 27, 2022
- Potential end of performance
- Sep 29, 2032
- Current value
- $220,916,162Base and exercised options
- Potential value (if all options are exercised)
- $942,781,169
Obligations by fiscal year of action
- FY2026: $36,129,771
- FY2025: $49,946,602
- FY2023: $25,066,667
- FY2022: $109,773,122
Total across 4 fiscal years: $220,916,162
Source: Federal Procurement Data System contract actions as published by SAM.gov and USAspending.gov; latest action recorded Nov 9, 2026. View on USAspending · Recipient on SAM.gov
Recipient
LocationSAN DIEGO, CA
UEIM9V9QTHR1H28
CAGE code417U0
Business sizeSmall businessSize at award, per the contracting officer
Organization typeCorporate not tax exempt
Parent companyMAPP BIOPHARMACEUTICAL INC.
Business types and certifications
For-profit organizationSubchapter S corporationCorporation (not tax-exempt)
As represented in SAM.gov at the time of the action.
Subcontracting network
The prime, the subcontractors on this award, and their own subcontractors.
Agency and place
Awarding and funding
- Awarded by
- Department of Health and Human Services
- Administration For Strategic Preparedness And Response
- BARDA - ASPR / DAAPPO / BARDA DCMA
- Funded by
- Department of Health and Human Services
- Administration For Strategic Preparedness And Response
- OFC ASST SEC FOR PREPARENESS RES
Place of performance
- Place of performance
- San Diego, California 92121-3823
- Congressional district (place of performance)
- CA-51As reported at the time of the action
Classification and competition
Classification
- Product or service (PSC)
- 6505DRUGS AND BIOLOGICALS (product)
Competition
- Extent competed
- Full and open competitionA
- Solicitation procedures
- Negotiated proposal/quoteNP
- Set-aside
- No set-aside used
- Contract pricing
- Cost plus fixed feeU
- Offers received
- 2
Solicitation and notices
- Solicitation ID
- 75A50121R00038(as reported)
- Solicitation date
- May 16, 2022
Contract details
- Subcontracting plan
- Plan not requiredB
- Cost Accounting Standards clause
- Not applicable exempt from CASX
- Certified cost or pricing data
- No
- Commercial procedures
- Commercial products/services procedures not usedD
- Government-furnished property
- Transaction does not use GFE/GFPN
- Bundled requirement
- Not bundledH
- Consolidated requirement
- Not consolidatedD
- Undefinitized action (terms not final)
- No
- Multi-year contract
- No
Linked notices
Notice | Notice ID | Type | Link | Posted |
|---|---|---|---|---|
Transaction history
Modification history
- Base award
- Sep 27, 2022Base obligation at award: $109,773,122
- Latest action
- Nov 9, 2026 — Other administrative actionModification P00024; administrative: no change in scope or value
- Latest substantive action
- Jul 8, 2026 — Supplemental agreement (within scope)Modification P00021; obligation change +$3,227,479
- Latest funding action
- Sep 18, 2026 — Funding onlyModification P00023; obligation change +$322,131; funding only: changes obligations, not scope
- Actions by type
- Base award1
- Other administrative action13
- Supplemental agreement (within scope)6
- Funding only2
- New work added (outside scope)1
- Change order1
- Option exercised1
Similar awards
PIID | Match | Awardee |
|---|---|---|
All contract data
All contract data
Every other field reported for this award, as of its latest reported action
Competition
- Evaluation preference
- No preference used
- Local area set-aside
- No
- Synopsized publicly (SAM.gov / FedBizOpps)
- Yes
- Simplified procedures for commercial items
- No
- A-76 (FAIR Act) action
- No
Pricing and financing
- Paid by purchase card
- No
Socio-economic and policy
- Recovered materials and sustainability
- No clauses included and no sustainability includedC
- EPA-designated product
- Not requiredE
- Clinger-Cohen Act planning (IT)
- No
Place and origin
- Domestic or foreign entity
- U.S. owned businessA
- Country of product or service origin
- United statesUSA
- Place of manufacture
- Mfg in U.S.D
Structure
- Award or IDV
- Award
- Award type
- Definitive contractD
- Awarding agency code
- 7500
- Awarding sub-tier code
- 7505
- Contracting office code
- 75A501
- Transactions recorded under this award key
- 25
Funding
- Funding agency code
- 7500
- Funding sub-tier code
- 7505
- Funding office code
- 750501